Andere talen Johnson & Johnson Swiss Exchange

Aandelen

JNJ

US4781601046

Beurs gesloten - Swiss Exchange Andere beurzen 17:36:28 25-05-2023			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
136 ^USD	-0,73%		-0,73%	-.--%

14/06	EU-regulator verplicht etiketupdates voor CAR-T kankertherapieën	RE
14/06	Johnson & Johnson rapporteert positieve langetermijnresultaten voor Talvey in multiple myeloom studie	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	09:31
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	14/06
EU regulator mandates label updates on CAR-T cancer therapies	14/06
J&J : essai encourageant dans le myélome multiple récidivant	14/06
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease	14/06
J&J : les promesses de l'ibrutinib dans la LLC	14/06
J&J : résultats prometteurs pour Imbruvica dans la leucémie	14/06
Johnson & Johnson Reports Positive Long-Term Results for Talvey in Multiple Myeloma Study	14/06
High-risk health workers can get routine Ebola vaccine, Gavi says	13/06
Xencor to Regain Exclusive Global Rights to CD20 x CD3 Bispecific T-Cell Engager	13/06
Xencor : J&J's Janssen Termintates Rights to Plamotamab	13/06
That's Stentertainment	13/06
High-risk health workers can get routine Ebola vaccine, says Gavi	13/06
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Press Release	12/06
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy	12/06
Cancer victims ask court to block J&J talc bankruptcy	12/06
Johnson & Johnson agrees to pay $700M to settle talcum lawsuit with dozens of states	12/06
Sector Update: Health Care Stocks Softer Late Afternoon	11/06
Sector Update: Health Care	11/06
Johnson and Johnson Talcum-Settlement Consent Judgments Filed -- Update	11/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

De geneesmiddelenpijplijn is goed gepositioneerd voor 2024, zegt J&J CFO

23 januari 2024 om 18:30 uur